High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.96B
-5.45%
1.493
+5.92%
1.95B
-6.02%
1.481
+10.53%
2.02B
-6.38%
1.634
-3.32%
Estimates Revision
The market is revising Upward the revenue expectations for Solventum Corporation (SOLV) for FY2025, with the revenue forecasts being adjusted by 0.62% over the past three months. During the same period, the stock price has changed by 17.79%.
Revenue Estimates for FY2025
Revise Upward
+0.62%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.38%
In Past 3 Month
Stock Price
Go Up
+17.79%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast SOLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOLV is 87.86 USD with a low forecast of 79.00 USD and a high forecast of 103.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 85.260
Low
79.00
Averages
87.86
High
103.00
Current: 85.260
Low
79.00
Averages
87.86
High
103.00
BTIG
Neutral -> Buy
upgrade
$100
2025-12-02
New
Reason
BTIG
Price Target
$100
2025-12-02
New
upgrade
Neutral -> Buy
Reason
BTIG upgraded Solventum to Buy from Neutral with a $100 price target.
BTIG
Ryan Zimmerman
Neutral -> Buy
upgrade
$100
2025-12-02
New
Reason
BTIG
Ryan Zimmerman
Price Target
$100
2025-12-02
New
upgrade
Neutral -> Buy
Reason
BTIG analyst Ryan Zimmerman upgraded Solventum to Buy from Neutral with a $100 price target. The firm believes the company will find its "footing" in 2026. The company's divestiture of its purification and filtration business helped reduce its debt, says BTIG, which cites Solventum's execution against guidance and reduced buy-side expectations for the upgrade. It finds the stock's setup "compelling" at current valuation levels.
UBS
Neutral
maintain
$77 -> $79
2025-11-10
Reason
UBS
Price Target
$77 -> $79
2025-11-10
maintain
Neutral
Reason
UBS raised the firm's price target on Solventum to $79 from $77 and keeps a Neutral rating on the shares. Solventum delivered strong Q3 results and proactively addressed 2026 margin concerns with a new $500M long-term cost savings plan, the analyst tells investors in a research note. While initial benefits may be modest, projected 2026 adjusted net income and EPS growth have been raised to 6%, supported by better-than-expected revenue trends, UBS says.
Piper Sandler
Jason Bednar
Overweight
maintain
$94 -> $98
2025-11-07
Reason
Piper Sandler
Jason Bednar
Price Target
$94 -> $98
2025-11-07
maintain
Overweight
Reason
Piper Sandler analyst Jason Bednar raised the firm's price target on Solventum to $98 from $94 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that included revenue of $2,096M/+2.7% organic and EPS of $1.50, another quarter of outperformance vs. consensus expectations and living up to the beat/raise call it previewed. This is the seventh consecutive quarter in which management has delivered upside vs. Street, and it's also the fourth guidance raise during that time, Piper adds.
UBS
Kevin Caliendo
Neutral
initiated
$77
2025-10-01
Reason
UBS
Kevin Caliendo
Price Target
$77
2025-10-01
initiated
Neutral
Reason
UBS analyst Kevin Caliendo initiated coverage of Solventum with a Neutral rating and $77 price target. The firm sees the company's growth moderating in the near term due to industry SKU rationalization and tougher compares. It views the shares as appropriately valued given Solventum's current portfolio setup.
Wells Fargo
Equal Weight
maintain
$79 -> $82
2025-09-14
Reason
Wells Fargo
Price Target
$79 -> $82
2025-09-14
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Solventum to $82 from $79 and keeps an Equal Weight rating on the shares. The firm is updating its price target on the stock to reflect the sale of the company's P&F business, the analyst tells investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Solventum Corp (SOLV.N) is 13.65, compared to its 5-year average forward P/E of 12.22. For a more detailed relative valuation and DCF analysis to assess Solventum Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Overvalued
5Y Average PE
12.22
Current PE
13.65
Overvalued PE
13.40
Undervalued PE
11.04
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
9.21
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
10.45
Undervalued EV/EBITDA
7.97
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.45
Current PS
0.00
Overvalued PS
1.61
Undervalued PS
1.30
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
SOLV News & Events
Events Timeline
(ET)
2025-11-07
09:55:01
Significant Early Gainers in Liquid Options on November 7th
2025-11-06 (ET)
2025-11-06
16:10:59
Solventum increases 2025 adjusted EPS forecast to $5.98-$6.08, up from $5.88-$6.03
2025-11-06
16:09:14
Solventum announces Q3 adjusted earnings per share of $1.50, surpassing consensus estimate of $1.43.
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/c7b56aad03612afc1f5526d78c6debdd07f54f561d7a266fd86dffa44bb9545d.png)
Preview
4.0
12-02BenzingaT-Mobile Analyst Changes Stance; Check Out Tuesday's Top 5 Upgrades
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/4fc98689a39b294bad2371a660cdb9e9f47df458b5494ef21e445e0da8e72247.png)
Preview
4.5
11-29Barron'sNovember's Top and Bottom Performing Stocks in the S&P 500
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/cfa5751ad9ff16fc5365caa5ccd9ded771020a86ecfdfd821849de0b0ca6ce68.png)
Preview
1.0
11-26PRnewswireSolventum to Participate in the 2025 Piper Sandler Healthcare Conference
Sign Up For More News
People Also Watch
FAQ
What is Solventum Corp (SOLV) stock price today?
What is Solventum Corp (SOLV)'s business?
What is the price predicton of SOLV Stock?
What is Solventum Corp (SOLV)'s revenue for the last quarter?
What is Solventum Corp (SOLV)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Solventum Corp (SOLV)'s fundamentals?
How many employees does Solventum Corp (SOLV). have?